Tscan Therapeutics Inc share price logo

Tscan Therapeutics Inc Share Price

NASDAQ: TCRX

Small Cap

$1.01

-0.02

(-1.46%)

as on

Tscan Therapeutics Inc Stock Performance

as on April 3, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $1.00
    $1.05
    downward going graph

    0.99%

    Downside

    3.96%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.88
    $2.57
    downward going graph

    12.63%

    Downside

    154.46%

    Upside

    downward going graph

Tscan Therapeutics Inc share price movements today

Previous Close
$1.03
Open
$1.00
Volume
1.2M
Day's Low - High
$1.00 - $1.05
52 Week Low - High
$0.88 - $2.57

Tscan Therapeutics Inc Historical Returns

1 Month Return
-6.48 %
3 Month Return
-0.98 %
1 Year Return
-8.18 %
3 Year Return
-54.09 %
5 Year Return
0 %

Tscan Therapeutics Inc Stock Fundamentals & Key Indicators

Check Tscan Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$57.5M

EPS (TTM)

-0.7325

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.63

Industry PE ratio

0

PEG Ratio

0

EBITDA

-130.9M

Revenue (TTM)

10.3M

Profit Margin

0.00%

Return On Equity TTM

-71.28%

Tscan Therapeutics Inc Stock Valuation

Track how Tscan Therapeutics Inc P/E has moved over time to understand its valuation trends.

Tscan Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-7.50x)

June 30, 2024

Industry (0.00x)

April 4, 2026

Today (-2.63x)

April 4, 2026

Highest (-0.45x)

March 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -2.63x

Tscan Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Tscan Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Tscan Therapeutics Inc image
Tscan Therapeutics Inc
BUY$57.5MNA-2.630.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$42.3B124.84%136.858.45%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$35.7BNA125.835.37%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$111.4B105.93%28.6632.94%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.5B60.41%18.3831.41%

Stock Returns calculator for Tscan Therapeutics Inc Stock including INR - Dollar returns

The Tscan Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 10Y

Tscan Therapeutics Inc investment value today

Current value as on today

₹99,076

Returns

-₹924

(-0.92%)

Returns from Tscan Therapeutics Inc Stock

-₹8,182 (-8.18%)

Dollar Impact

₹7,258 (+7.26%)

Analyst Recommendation on Tscan Therapeutics Inc Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Tscan Therapeutics Inc. Average target price of $6

Tscan Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Tscan Therapeutics Inc.

What analysts predicted

83.17%UPSIDE

Target Price

$6

Current Price

$1.01

Analyzed by

12 Analysts

Target

$6.00

Tscan Therapeutics Inc target price $6, a slight upside of 83.17% compared to current price of $1.01. According to 12 analysts rating.

Tscan Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Tscan Therapeutics Inc Stock has increased by 114% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:114% versus previous 30 day period

Tscan Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
3
7
0
0
1
0
2
3
2
2
Gross Profit
3
5
0
0
1
0
2
3
1
1
Operating Income
-24
-21
-31
-34
-32
-36
-36
-38
-37
-23
EBITDA
-20
-17
-27
-29
-27
-34
-32
-35
-34
-30
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
1
1
1
1
1
0
0
0
0
0
Income Before Tax
-22
-19
-30
-31
-29
-35
-34
-36
-35
-22
Income Tax Expense
-1
-1
-1
-1
-
1
-
-
-
-
Net Income
-22
-19
-30
-31
-29
-35
-34
-36
-35
-22
Net Profit Margin
-591.64%
-271.99%
-5325.44%
-5906.90%
-2849.09%
-5384.81%
-1571.95%
-1201.30%
-1422.14%
-895.09%

Tscan Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
1
10
13
21
2
10
Gross Profit
-9
-19
10
13
21
2
7
Operating Income
-14
-26
-48
-66
-93
-134
-135
EBITDA
-13
-25
-45
-59
-80
-119
-132
Interest Expense
-
-
0
1
3
3
2
Depreciation
0
1
3
5
5
4
2
Income Before Tax
-13
-26
-48
-66
-89
-127
-129
Income Tax Expense
0
0
3
0
5
-
-
Net Income
-13
-26
-48
-66
-89
-127
-129
Net Profit Margin
0.00%
-2408.02%
-479.49%
-489.26%
-423.86%
-4527.66%
-1256.81%

Tscan Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-19
-30
-31
-29
-35
-34
-36
-35
-22
Operating Cash Flow
-23
-29
-26
-27
-27
-37
-33
-32
-32
Investing Cash Flow
1
36
-33
-82
27
13
48
32
14
Financing Cash Flow
0
0
161
1
45
0
0
-
0
Change in Cash
-21
7
101
-109
45
-24
15
0
-17

Tscan Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-26
-48
-66
-89
-127
-129
Operating Cash Flow
-3
-48
-66
-61
-110
-135
Investing Cash Flow
-4
-9
-4
-60
-52
109
Financing Cash Flow
0
189
29
135
208
0
Change in Cash
-6
131
-41
13
45
-26

Global Institutional Holdings in Tscan Therapeutics Inc

Funds
Holdings
Alphabet Inc
1.89%
UBS Group AG
0.71%
Geode Capital Management, LLC
0.99%
Jane Street Group LLC
0.68%
Propel Bio Management LLC
3.68%
See all

Insights on Tscan Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 2.51M → 2.56M (in $), with an average increase of 2.2% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -36.95M → -22.97M (in $), with an average increase of 29.5% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 58.8% return, outperforming this stock by 111.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.3% return, outperforming this stock by 43.5%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 6 months, TCRX stock has moved down by -52.1%

About Tscan Therapeutics Inc

harnessing novel t cell systems to extend the promise of immunotherapy
OrganisationTscan Therapeutics Inc
Headquarters830 Winter Street, Waltham, MA, United States, 02451
CEODr. Gavin MacBeath Ph.D.
E-voting on sharesClick here to vote

Key Management of Tscan Therapeutics Inc

Name

Title

Dr. Gavin MacBeath Ph.D.

CEO & Director

Dr. Chrystal U. Louis M.D., M.P.H.

Chief Medical Officer

Dr. Stephen J. Elledge Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Mr. Leiden Dworak M.B.A.

VP of Finance & Principal Accounting Officer

Mr. Ray Lockard M.B.A.

Senior Vice President & Head of Quality

Mr. Jason A. Amello CPA

CFO & Treasurer

Mr. Tomasz Kula Ph.D.

Co-Founder & Member of Advisory Board

Dr. Zoran Zdraveski J.D., Ph.D.

Chief Legal & Strategy Officer and Company Secretary

Ms. Ann Hargraves

Senior Vice President of Human Resources

Dr. Shrikanta Chattopadhyay M.D.

Senior VP & Head of Translational Medicine

FAQs

What is Tscan Therapeutics Inc share price today?

Tscan Therapeutics Inc share price today is $1.01 as on at the close of the market. Tscan Therapeutics Inc share today touched a day high of $1.05 and a low of $1.

What is the 52 week high and 52 week low for Tscan Therapeutics Inc share?

Tscan Therapeutics Inc share touched a 52 week high of $2.57 on and a 52 week low of $0.88 on . Tscan Therapeutics Inc stock price today i.e. is closed at $1.01,which is 60.70% down from its 52 week high and 14.46% up from its 52 week low.

What is Tscan Therapeutics Inc's market capitalisation today?

Tscan Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Tscan Therapeutics Inc Stock (TCRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Tscan Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Tscan Therapeutics Inc Shares that will get you 1.4851 shares as per Tscan Therapeutics Inc share price of $1.01 per share as on April 3, 2026 at 1:29 am IST.

What is the minimum amount required to buy Tscan Therapeutics Inc Stock (TCRX) from India?

Indian investors can start investing in Tscan Therapeutics Inc (TCRX) shares with as little as ₹92.67 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹926.70 in Tscan Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Tscan Therapeutics Inc share’s latest price of $1.01 as on April 3, 2026 at 1:29 am IST, you will get 9.9010 shares of Tscan Therapeutics Inc. Learn more about fractional shares .